Τόμος 24 (2010) – Τεύχος 2 – Άρθρο 71 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 2 – Article 71 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Thessaly, Karditsa, Greece, and Laboratory of Drug Development, Institute of Technology and Management of Agricultural Ecosystems (Ι.ΤΕ.M.Α.), Centre for Research and Technology of Thessaly (CERETETH), Karditsa, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Schneider R., Dorn C.R., Taylor D.O.: Factors influencing canine mammary cancer development and postsurgical survival. J. Natl. Cancer Inst. 43: 1249-1261 (1969)

3. Misdorp W, Else R., Hellmen E.: Histological classification of mammary tumors of dog and cat. In: WHO International Histological Classification of Tumors of Domestic Animals 2nd series Washington DC Armed Forces Institute of Pathology, Americal Registry of Pathology (2001)

4. MacEwen E.G., Harvey H.J., Patnaik A.K., Mooney S., Hayes A., Kurzman I., Hardy W.D.,Jr.: Evaluation of effects of levamisole and surgery on canine mammary cancer. J. Biol. Response Mod. 4: 418-426 (1985)

5. Hahn K.A., Knapp D.W., Richardson R.C., Matlock C.L.: Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. J. Am. Vet. Med. Assoc. 200: 355-357 (1992)

6. Simon D., Schoenrock D., Baumgartner W., Nolte I.: Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J. Vet. Intern. Med. 20: 1184-1190 (2006)

7. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66: 11851-11858 (2006)

8. Albert D.H., Tapang P., Magoc T.J., Pease L.J., Reuter D.R., et al., Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5: 995-1006 (2006)

9. Hellmen E.: Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. In Vitro Cell. Dev. Biol. 28A: 309-319 (1992)

10. Mosmann T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth 65: 55-63 (1983)

11. Jemal A., Siegel R., Ward E. et al.: Cancer statistics. CA Cancer J. Clin. 58: 71-96 (2008)

12. Slamon D.J.: Proto-oncogenes and human cancers. N. Engl. J. Med. 317: 955-957 (1987)

13. Robinson A.G., Turbin D., Thomson T. et al.: Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin. Breast Cancer 7: 254-261 (2006)

14. Tanno S., Ohasaki Y., Nakanishi K., Toyoshima E., Kikuchi K.: Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (Iressa, ZD1839). Oncol. Rep. 12: 1053-1057 (2004)

15. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M.: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7: 3129–3140 (2008)

16. Burris H.A.: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib”. Oncologist 9 (Suppl 3): 10–15 (2004)

17. Qu L., Tang X.: Bexarotene: a promising anticancer agent. Cancer Chemother. Pharmacol. 65: 201-205 (2010)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr